RAS AL KHAIMAH'S AL HAMRA TARGETS OVERSEAS INVESTORS WITH A MONTH-LONG, SPECIAL ACTIVATION AT HARRODS IN LONDON

Link to Press Kit

RAS AL KHAIMAH, UAE, Aug. 5, 2024 /PRNewswire/ -- Al Hamra, a pioneering lifestyle developer and real estate investment company in Ras Al Khaimah, will be targeting UK and GCC investors and residents via a special activation in London at the world's leading luxury department store, Harrods.

In a first for a regional developer, and running for the whole month of August, Al Hamra's activation on Harrods' fifth floor will showcase the exclusive luxury living options at a range of recently launched premium and ultra-luxury residential properties to potential investors.

Part of a wider initiative to connect with target audiences in key locations, Al Hamra's Harrods activation will allow potential investors to explore Destination Al Hamra in Ras Al Khaimah and the premium lifestyle it offers.

Among the pipeline of exciting projects being showcased to Harrods visitors is the Waldorf Astoria Residences Ras Al Khaimah – the emirate's most prestigious address. Comprising 43 ultra-luxury residences, penthouses, sky palaces and villas, the development promises unparalleled living experiences with palatial interiors and unrestricted views of the Arabian Gulf and the region's first integrated gaming resort – The Wynn Al Marjan Island.

Al Hamra Waterfront, another premium residential project located on the shores of the Royal Yacht Club of Ras Al Khaimah, offers 622 apartments, 19 townhouses and a range of world-class leisure and recreational amenities across five residential towers.

With superb travel links and a business-friendly environment for investors and entrepreneurs, Ras Al Khaimah's property values are continuing to rise steadily. Demand is at an all-time high, driven by sophisticated investors from a range of nationalities who are choosing the Emirates as a place in which to live, work, play and invest.

Offering an attractive business environment, the Emirate was named the fourth-best city for expats to live and work in by the InterNations Annual Report 2023, and, in 2019, Ras Al Khaimah was ranked 30^th for ease of doing business among 190 economies in the World Bank's global survey.

Benoy Kurien, Group CEO of Al Hamra, said: "We are always seeking new and innovative ways to directly communicate with investors and buyers in our key markets, and are delighted to be partnering with Harrods – a brand that shares our values of premium excellence – on this first-of-its-kind activation for Al Hamra. The Al Hamra team will be present on the ground in the heart of London for the entire month of August, highlighting its ultra-luxury and premium residential projects and the destination's unparalleled waterfront lifestyle offering to potential new investors.

"The United Kingdom is one of Al Hamra's primary target markets, and a majority of residents and investors across Al Hamra's extensive residential portfolio are from the UK and Europe. Our expertise in delivering innovative lifestyle experiences and products in Ras Al Khaimah, combined with the Emirate's visionary approach, has created an array of premium real estate opportunities.

"Attracted to Al Hamra's luxurious waterfront lifestyle, these developments offer a wide range of amenities for residents and tourists alike, and allied with Ras Al Khaimah's tax-free, business-friendly environment, we have seen high levels of demand from this all-important market and look forward to welcoming visitors to our pop up."

The Harrods activation will be launched under the umbrella of Al Hamra's strategic five-year plan, which outlines several targets between 2023 and 2027. It focuses on diversifying revenue streams, expanding services, and leveraging existing assets to create new and sustained opportunities for growth via a three-pronged approach that brings hospitality, retail, and real estate to the forefront.

For more information on Al Hamra, please visit here.

Note to Editors

About Al Hamra:

Al Hamra is a leading lifestyle development and investment company, based in Ras Al Khaimah, UAE. The company has been instrumental in shaping the Northern Emirate's real estate and investment landscape across residential, retail, hospitality, leisure, and entertainment since its inception in 2003.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

RAS AL KHAIMAH'S AL HAMRA TARGETS OVERSEAS INVESTORS WITH A MONTH-LONG, SPECIAL ACTIVATION AT HARRODS IN LONDON

SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).

This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.

According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×10⁹ PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.

By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.

"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."

About MVR-T3011

MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.

About ImmVira

ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS^® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients